Nutriband (NASDAQ:NTRB) Trading Down 3.9% – Here’s What Happened

Posted by Scott Moore on Jul 25th, 2026

Nutriband Inc. (NASDAQ:NTRB – Get Free Report)’s stock price was down 3.9% on Thursday . The company traded as low as $2.92 and last traded at $2.93. 13,734 shares traded hands during mid-day trading, an increase of 8% from the average session volume of 12,696 shares. The stock had previously closed at $3.05.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded Nutriband from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 1st. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Reduce”.

Read Our Latest Report on Nutriband

Nutriband Stock Up 1.7%

The company has a 50 day simple moving average of $3.26 and a 200-day simple moving average of $3.82. The stock has a market cap of $36.22 million, a price-to-earnings ratio of -1.16 and a beta of 1.93.

Nutriband (NASDAQ:NTRB – Get Free Report) last issued its earnings results on Thursday, June 11th. The company reported ($0.10) EPS for the quarter. Nutriband had a negative return on equity of 112.64% and a negative net margin of 448.25%.The firm had revenue of $0.43 million during the quarter.

Institutional Trading of Nutriband

An institutional investor recently bought a new position in Nutriband stock. Cogent Private Wealth Inc. bought a new position in shares of Nutriband Inc. (NASDAQ:NTRB – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 16,014 shares of the company’s stock, valued at approximately $73,000. Cogent Private Wealth Inc. owned 0.13% of Nutriband as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 19.70% of the company’s stock.

Nutriband Company Profile

(Get Free Report)

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility.